Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Cougar Biotechnology
Evaluate
February 10, 2014
Puma leaps, but how big is the T790M opportunity?
December 06, 2013
Puma roars but neratinib's real value remains opaque
June 11, 2013
EP Vantage interview – J&J draws a bead on oncology targets
May 31, 2013
A few stars shine among the most valuable unpartnered assets
October 22, 2012
Puma investors look for second lightning strike
November 24, 2011
History not on Gilead's side in high stakes gamble on Pharmasset
October 06, 2011
New company Puma roars with Pfizer licensing deal
January 04, 2011
Clinical and regulatory events over the Christmas period
February 10, 2010
Event – Pivotal lung cancer data could see Novelos soar
July 13, 2009
Event - Poniard approaching pivotal phase III data point
June 19, 2009
Companies still desperate for a partner
Load More
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
May 15, 2023
Pharma’s Biggest Spenders 2022 Infographic
May 03, 2023
Gene Editing: Overhyped or Unstoppable Tide?
Editor's Picks
May 16, 2023
Heightened US antitrust fears rattle biopharma
May 11, 2023
2023’s biggest launches: the story so far
May 17, 2023
Viking’s Voyage is not over yet
May 09, 2023
Gene editing: overhyped or unstoppable tide?
May 16, 2023
A slow (and low) year for FDA approvals